RxDoctor Payments Data

Joseph Valdez, MD

Family Medicine · Pasadena, TXNPI 1851465355

Payments from drug & device makers

$7,134in general payments, 2019–2025

Across 270 payments — averaging $26.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$2K
  • Sanofi-aventis U.S. LLC$995
  • Bayer$855
  • Lilly USA, LLC$390
  • Indivior Inc.$122
  • plus $272 from 9 others

What the payments were for

  • Food & beverage$7,128100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,134 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$37,463
Medicare patients
50
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Soliqua 100-33Insulin Glargine/Lixisenatide35$68,700
Xigduo XrDapaglifloz Propaned/Metformin36$36,264
FarxigaDapagliflozin Propanediol18$15,594
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl78$9,523
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$3,345
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$3,235
Raloxifene Hcl47$2,771
ProgesteroneProgesterone, Micronized49$2,254
Testosterone Cypionate18$1,555
Atorvastatin Calcium192$1,530
Bupropion XlBupropion Hcl63$1,349
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide60$1,204
Levothyroxine Sodium150$1,197
Losartan Potassium116$1,185
Metoprolol Succinate73$993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCSoliqua 100-33$995$68,70035 claims
AstraZenecaFarxiga$2,635$15,59418 claims
Indivior Inc.Suboxone$122$3,23513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Pasadena

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →